HRP20130738T1 - Postupak lijeäśenja ili profilakse - Google Patents
Postupak lijeäśenja ili profilakse Download PDFInfo
- Publication number
- HRP20130738T1 HRP20130738T1 HRP20130738TT HRP20130738T HRP20130738T1 HR P20130738 T1 HRP20130738 T1 HR P20130738T1 HR P20130738T T HRP20130738T T HR P20130738TT HR P20130738 T HRP20130738 T HR P20130738T HR P20130738 T1 HRP20130738 T1 HR P20130738T1
- Authority
- HR
- Croatia
- Prior art keywords
- substituted
- phenyl
- benzyl
- alkyl
- use according
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims 3
- 238000011282 treatment Methods 0.000 title claims 3
- 238000011321 prophylaxis Methods 0.000 title 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 21
- ZUOUZKKEUPVFJK-UHFFFAOYSA-N diphenyl Chemical class C1=CC=CC=C1C1=CC=CC=C1 ZUOUZKKEUPVFJK-UHFFFAOYSA-N 0.000 claims 16
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 13
- 125000000217 alkyl group Chemical group 0.000 claims 12
- 125000003545 alkoxy group Chemical group 0.000 claims 10
- 239000000584 angiotensin II type 2 receptor blocker Substances 0.000 claims 10
- -1 phenyloxy, benzyl Chemical group 0.000 claims 10
- 235000010290 biphenyl Nutrition 0.000 claims 9
- 239000004305 biphenyl Substances 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 9
- 125000001624 naphthyl group Chemical group 0.000 claims 7
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 6
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 6
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 6
- 150000001875 compounds Chemical class 0.000 claims 6
- 239000001257 hydrogen Substances 0.000 claims 6
- 208000004296 neuralgia Diseases 0.000 claims 6
- 208000021722 neuropathic pain Diseases 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- CCGOFLIRJQWGAA-UHFFFAOYSA-N N-benzyl-2-phenyl-6-phenylmethoxyaniline Chemical group C(C1=CC=CC=C1)OC=1C(=C(C=CC=1)C1=CC=CC=C1)NCC1=CC=CC=C1 CCGOFLIRJQWGAA-UHFFFAOYSA-N 0.000 claims 3
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 3
- 229910052799 carbon Inorganic materials 0.000 claims 3
- 125000001072 heteroaryl group Chemical group 0.000 claims 3
- 150000002431 hydrogen Chemical class 0.000 claims 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 3
- 229910052757 nitrogen Inorganic materials 0.000 claims 3
- 229910052760 oxygen Inorganic materials 0.000 claims 3
- 239000001301 oxygen Substances 0.000 claims 3
- 230000002093 peripheral effect Effects 0.000 claims 3
- 229910052717 sulfur Inorganic materials 0.000 claims 3
- 239000011593 sulfur Substances 0.000 claims 3
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims 2
- 208000028389 Nerve injury Diseases 0.000 claims 2
- 150000001735 carboxylic acids Chemical group 0.000 claims 2
- 239000003085 diluting agent Substances 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 2
- 230000008764 nerve damage Effects 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical group [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims 1
- 150000001408 amides Chemical group 0.000 claims 1
- 125000003118 aryl group Chemical group 0.000 claims 1
- 150000007942 carboxylates Chemical group 0.000 claims 1
- 125000004122 cyclic group Chemical group 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 125000000623 heterocyclic group Chemical group 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- UUEVFMOUBSLVJW-UHFFFAOYSA-N oxo-[[1-[2-[2-[2-[4-(oxoazaniumylmethylidene)pyridin-1-yl]ethoxy]ethoxy]ethyl]pyridin-4-ylidene]methyl]azanium;dibromide Chemical compound [Br-].[Br-].C1=CC(=C[NH+]=O)C=CN1CCOCCOCCN1C=CC(=C[NH+]=O)C=C1 UUEVFMOUBSLVJW-UHFFFAOYSA-N 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical group [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Chemical group 0.000 claims 1
- 125000005541 phosphonamide group Chemical group 0.000 claims 1
- 125000003107 substituted aryl group Chemical group 0.000 claims 1
- 229940124530 sulfonamide Drugs 0.000 claims 1
- 150000003456 sulfonamides Chemical group 0.000 claims 1
- 230000000699 topical effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/88—Oxygen atoms
- C07D239/90—Oxygen atoms with acyclic radicals attached in position 2 or 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Urology & Nephrology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Diabetes (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Biochemistry (AREA)
- Anesthesiology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
Claims (13)
1. Uporaba učinkovite količine antagonista AT2 receptora, koja je proizvoljno u obliku pripravka koji sadrži farmaceutski prihvatljiv nosač i/ili razrjeđivač, za proizvodnju lijeka za liječenje, sprečavanje ili smanjivanje neuropatske boli kod subjekta;
naznačena time da je antagonist AT2 receptora odabran od spojeva koji su prikazani sa formulom (I):
[image]
pri čemu:
R1 i R2 su neovisno odabrani od H, benzila, supstituiranog benzila, fenila, supstituiranog fenila, C1-6alkila, supstituiranog C1-6alkila, C3-6cikloalkila, supstituiranog C3-6cikloalkila, i heteroaril, pod uvjetom da oba R1 i R2 nisu vodik,
R4 je odabran od karboksilata, karboksilne kiseline, sulfata, fosfata, sulfonamida, fosfonamida ili amida,
X je odabran od CH, dušika, sumpora ili kisika pod uvjetom da kada X je sumpor ili kisik jedan od R1 ili R2 je odsutan,
Y je odabran od sumpora, kisika ili N-RN, gdje RN je odabran od H, C1-6alkila, supstituiranog C1-6alkila, arila, supstituiranog arila, benzila, supstituiranog benzila, C1-4alkilarila, supstituiranog C1-4alkilarila, OH, ili NH2,
G je peteročlani ili šesteročlani, homoaromatski ili nezasićeni, supstituirani ili nesupstituirani, heterociklički prsten koji uključuje, ali nije ograničen na slijedeće prstenaste sustave:
[image]
[image]
gdje oznaka '*' označava vezu koja se dijeli između kondenziranih prstenova 'A' i
'G',
R5 je odabran od H, C1-6alkila, fenila, supstituiranog fenila, supstituiranog C1-6alkila, C1-6alkoksi, ili supstituiranog C1-6alkoksi,
R6 i R8 su neovisno odabrani od H, C1-6alkila, supstituiranog C1-6alkila, C1-6alkoksi, supstituiranog C1-6alkoksi, fenila, feniloksi, benzila, benziloksi, benzilamino, bifenila, supstituiranog bifenila, bifeniloksi, supstituiranog bifeniloksi, naftil, supstituiranog naftila, uz uvjet da jedan od R6 ili R8 nije vodik, i
R7 je odabran od fenila, supstituiranog fenila, benzila, supstituiranog benzila, bifenila, supstituiranog bifenila, bifenilmetilena, supstituiranog bifenilmetilena, naftila, supstituiranog naftila, naftilmetilena, i supstituiranog naftilmetilena,
ili njihova farmaceutski kompatibilna sol.
2. Uporaba prema zahtjevu 1, naznačena time da je antagonist AT2 receptora odabran od spojeva, ili njihovih farmaceutski kompatibilnih soli, prikazanih sa formulom (IX):
[image]
pri čemu:
X je odabran od CH ili dušika,
R1 i R2 su neovisno odabrani od fenila, supstituiranog fenila, benzila, supstituiranog benzila, C1-6alkila, supstituiranog C1-6alkila, C3-6cikloalkila, supstituiranog C3-6cikloalkila i heteroarila,
R5 je odabran od vodika, C1-6alkila, fenila, supstituiranog fenila, supstituiranog C1-6alkila, C1-6alkoksi, i supstituiranog C1-6alkoksi, i
R7 je odabran od je odabran od fenila, supstituiranog fenila, benzila, supstituiranog benzila, bifenila, supstituiranog bifenila, bifenilmetilena, supstituiranog bifenilmetilena, naftila, supstituiranog naftila, naftilmetilena, i supstituiranog naftilmetilena.
3. Uporaba prema zahtjevu 1, naznačena time da je antagonist AT2 receptora odabran od spojeva, ili njihovih farmaceutski kompatibilnih soli, prikazanih sa formulom (X):
[image]
pri čemu:
X je odabran od CH ili dušika,
R1 i R2 su neovisno odabrani od fenil, supstituiranog fenila, benzila, supstituiranog benzila, C1-6alkila, supstituiranog C1-6alkila, C3-6cikloalkila, supstituiranog C3-6cikloalkila i heteroarila, i
R6 i R8 su neovisno odabrani od H, C1-6alkila, supstituiranog C1-6alkila, C1-6alkoksi, supstituiranog C1-6alkoksi, fenila, feniloksi, benzila, benziloksi, benzilamino, bifenila, supstituiranog bifenil, bifeniloksi, supstituiranog bifeniloksi, naftila, supstituiranog naftila, uz uvjet da jedan od R6 ili R8 nije vodik.
4. Uporaba prema bilo kojem zahtjevu 1 ili 2, naznačena time da je antagonist AT2 receptora odabran od spojeva, ili njihovih farmaceutski kompatibilnih soli, prikazanih sa formulom (IX), pri čemu R1 i R2 su fenil, X je CH, R5 je vodik ili C1-4alkil, i R7 je odabran od supstituiranog benzila.
5. Uporaba prema bilo kojem zahtjevu 1, 2 ili 4, naznačena time da je antagonist AT2 receptora odabran od spojeva, ili njihovih farmaceutski kompatibilnih soli, prikazanih sa formulom (IX), R5 je vodik i R7 je odabran od 4-(N,N-dimetilamino)-3-metilbenzila, 4-metoksi-3-metilbenzila, 4-amino-3-metilbenzila.
6. Uporaba prema zahtjevu 3, naznačena time da je antagonist AT2 receptora odabran od spojeva, ili njihovih farmaceutski kompatibilnih soli, prikazanih sa formulom (X), pri čemu su R1 i R2 neovisno odabrani od fenila ili supstituiranog fenila, X je CH, R4 je karboksilna kiselina, R6 je odabran od C1-6alkila, supstituiranog C1-6alkila, C1-6alkoksi, supstituiranog C1-6alkoksi, fenila, feniloksi, i R8 je odabran od H, fenila, feniloksi, benzila, benziloksi, benzilamino, bifenila, supstituiranog bifenila, bifeniloksi, supstituiranog bifeniloksi, naftila, i supstituiranog naftila.
7. Uporaba prema bilo kojem zahtjevu 1 do 6, naznačena time da se antagonist AT2 receptor daje u obliku pripravka koji sadrži farmaceutski prihvatljiv nosač ili razrjeđivač.
8. Uporaba prema zahtjevu 7, naznačena time da se pripravak daje načinom davanja koji je odabran od injekcije, topikalne primjene ili oralnim načinom, kroz period vremena i u količini, koja je učinkovita za liječenje ili sprečavanje neuropatske boli.
9. Uporaba prema bilo kojem zahtjevu 1 do 8, naznačena time da neuropatska bol je periferna neuropatska bol.
10. Uporaba prema zahtjevu 9, naznačena time da periferna neuropatska bol potječe od mehaničke ozljede živca ili biokemijske ozljede živca.
11. Uporaba prema zahtjevu 9, naznačena time da periferna neuropatska bol potječe od bolne dijabetičke neuropatije (PDN) ili povezanog stanja.
12. Uporaba prema bilo kojem zahtjevu 1 do 11, naznačena time da je antagonist AT2 receptora odabran od:
2-(Difenil)-5-benziloksi-6-metoksi-1,2,3,4-tetrahidroizokinolin-3-karboksilne kiseline (PD-126,055) ili njezinog enantiomera;
S(+)-1-[[4-dimetilamino)-3-metilfenil]metil]-5-(difenilacetil)-4,5,6,7-tetrahidro-1H-imidazo-[4,5c]-piridin-6-karboksilne kiseline (PD-123,319); i
S(+)-1-[[4-metoksi-3-metilfenil]metil]-5-(difenilacetil)-4,5,6,7-tetrahidro-1H-imidazo(4,5c)piridin-6-karboksilne kiseline (PD-121,981).
13. Uporaba prema zahtjevu 12 naznačena time da antagonist AT2 receptora je:
2-(Difenil)-5-benziloksi-6-metoksi-1,2,3,4-tetrahidroizokinolin-3-karboksilna kiselina (PD-126,055) ili njezin enantiomer.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2004907332A AU2004907332A0 (en) | 2004-12-24 | Method of Treatment or Prophylaxis | |
| PCT/AU2005/001975 WO2006066361A1 (en) | 2004-12-24 | 2005-12-23 | Method of treatment or prophylaxis |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130738T1 true HRP20130738T1 (hr) | 2013-10-25 |
Family
ID=36601295
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130738TT HRP20130738T1 (hr) | 2004-12-24 | 2013-08-06 | Postupak lijeäśenja ili profilakse |
Country Status (17)
| Country | Link |
|---|---|
| US (5) | US7795275B2 (hr) |
| EP (3) | EP2650010A1 (hr) |
| JP (1) | JP4966202B2 (hr) |
| CN (3) | CN101087619B (hr) |
| CY (1) | CY1114424T1 (hr) |
| DK (1) | DK1830869T3 (hr) |
| ES (1) | ES2425567T3 (hr) |
| HK (1) | HK1103364A1 (hr) |
| HR (1) | HRP20130738T1 (hr) |
| ME (1) | ME01597B (hr) |
| NZ (1) | NZ555334A (hr) |
| PL (1) | PL1830869T3 (hr) |
| PT (1) | PT1830869E (hr) |
| RS (1) | RS52927B (hr) |
| SI (1) | SI1830869T1 (hr) |
| WO (1) | WO2006066361A1 (hr) |
| ZA (3) | ZA200704909B (hr) |
Families Citing this family (50)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2425567T3 (es) | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Método de tratamiento o profilaxis |
| CN102885818B (zh) * | 2006-03-20 | 2016-05-04 | 诺华股份有限公司 | 治疗或预防炎性痛的方法 |
| CA2665476A1 (en) * | 2006-10-05 | 2008-04-10 | Cv Therapeutics, Inc. | Bicyclic nitrogen-containing heterocyclic compounds for use as stearoyl coa desaturase inhibitors |
| US20090105283A1 (en) * | 2007-04-11 | 2009-04-23 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US20080255161A1 (en) * | 2007-04-11 | 2008-10-16 | Dmitry Koltun | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| US7828840B2 (en) | 2007-11-15 | 2010-11-09 | Med Institute, Inc. | Medical devices and methods for local delivery of angiotensin II type 2 receptor antagonists |
| CA2740389A1 (en) * | 2008-10-15 | 2010-05-20 | Gilead Sciences, Inc. | 3-hydroquinazolin-4-one derivatives for use as stearoyl coa desaturase inhibitors |
| US20100267752A1 (en) * | 2008-10-15 | 2010-10-21 | Gilead Palo Alto, Inc. | 3-HYDROQUINAZOLIN-4-ONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS |
| EP2525795B1 (en) * | 2010-01-19 | 2015-10-21 | Spinifex Pharmaceuticals Pty Ltd | Methods and compositions for improved nerve conduction velocity |
| DE102010013075A1 (de) | 2010-03-26 | 2011-09-29 | B. Braun Melsungen Ag | Antimikrobielle Wundauflage |
| GB201007286D0 (en) | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| JP5948326B2 (ja) | 2010-07-21 | 2016-07-06 | ノバルティス アーゲー | テトラヒドロイソキノリン誘導体の塩および溶媒和物 |
| GB201020179D0 (en) | 2010-11-29 | 2011-01-12 | Astex Therapeutics Ltd | New compounds |
| CN108707151B (zh) | 2011-08-23 | 2022-06-03 | 阿萨纳生物科技有限责任公司 | 嘧啶并-哒嗪酮化合物及其用途 |
| GB201118656D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118675D0 (en) | 2011-10-28 | 2011-12-14 | Astex Therapeutics Ltd | New compounds |
| GB201118654D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| GB201118652D0 (en) | 2011-10-28 | 2011-12-07 | Astex Therapeutics Ltd | New compounds |
| WO2013102242A1 (en) | 2012-01-06 | 2013-07-11 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic compounds and methods for their use |
| US20150011565A1 (en) * | 2012-01-25 | 2015-01-08 | Spinifex Pharmaceuticals Pty Ltd | Heterocyclic Compounds and Methods For Their Use |
| EP2807171B1 (en) | 2012-01-25 | 2020-08-12 | Novartis AG | Heterocyclic compounds and methods for their use |
| GB201209609D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201209613D0 (en) | 2012-05-30 | 2012-07-11 | Astex Therapeutics Ltd | New compounds |
| GB201307577D0 (en) | 2013-04-26 | 2013-06-12 | Astex Therapeutics Ltd | New compounds |
| PL3019477T3 (pl) | 2013-07-08 | 2021-11-22 | Novartis Ag | Związki heterocykliczne i sposoby ich stosowania |
| KR102508139B1 (ko) | 2013-09-30 | 2023-03-08 | 에프엠씨 코포레이션 | 발포된 제형에 의한 고랑내 종자 처리 방법 |
| ES2734060T3 (es) | 2014-01-17 | 2019-12-04 | Cardioxyl Pharmaceuticals Inc | Donadores de nitroxilo de N-hidroximetanosulfonamida |
| JO3512B1 (ar) | 2014-03-26 | 2020-07-05 | Astex Therapeutics Ltd | مشتقات كينوكسالين مفيدة كمعدلات لإنزيم fgfr كيناز |
| PL3122358T3 (pl) | 2014-03-26 | 2021-06-14 | Astex Therapeutics Ltd. | Połączenia inhibitorów fgfr i cmet w leczeniu nowotworu |
| RU2715893C2 (ru) | 2014-03-26 | 2020-03-04 | Астекс Терапьютикс Лтд | Комбинации ингибитора fgfr и ингибитора igf1r |
| AR100936A1 (es) | 2014-06-24 | 2016-11-09 | Fmc Corp | Formulaciones de espumas y concentrados emulsionables |
| ES2792876T3 (es) | 2015-01-13 | 2020-11-12 | Novartis Ag | Derivados de pirrolidina como antagonistas de angiotensina II tipo 2 |
| JOP20200201A1 (ar) | 2015-02-10 | 2017-06-16 | Astex Therapeutics Ltd | تركيبات صيدلانية تشتمل على n-(3.5- ثنائي ميثوكسي فينيل)-n'-(1-ميثيل إيثيل)-n-[3-(ميثيل-1h-بيرازول-4-يل) كينوكسالين-6-يل]إيثان-1.2-ثنائي الأمين |
| WO2016142867A1 (en) | 2015-03-12 | 2016-09-15 | Novartis Ag | Heterocyclic compounds and methods for their use |
| US10478494B2 (en) | 2015-04-03 | 2019-11-19 | Astex Therapeutics Ltd | FGFR/PD-1 combination therapy for the treatment of cancer |
| CN106478502B (zh) * | 2015-08-29 | 2021-04-27 | 上海翰森生物医药科技有限公司 | 1,2,3,4-四氢异喹啉衍生物、其制备方法和应用 |
| HUE057090T2 (hu) | 2015-09-23 | 2022-04-28 | Janssen Pharmaceutica Nv | BI-heteroaril-szubsztituált 1,4-benzodiazepinek és alkalmazásuk rák kezelésében |
| BR112018005637B1 (pt) | 2015-09-23 | 2023-11-28 | Janssen Pharmaceutica Nv | Compostos derivados de quinoxalina, quinolina e quinazolinona,composições farmacêuticas que os compreende, e uso dos referidos compostos |
| AU2016378184B2 (en) | 2015-12-23 | 2022-04-21 | Fmc Corporation | In situ treatment of seed in furrow |
| WO2018001997A1 (en) | 2016-06-27 | 2018-01-04 | Ratiopharm Gmbh | Crystalline calcium salt of (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinoline carboxylic acid |
| WO2018172950A1 (en) | 2017-03-23 | 2018-09-27 | Novartis Ag | Anhydrous crystalline forms of sodium (s)-2-(diphenylacetyl)-1,2,3,4-tetrahydro-6-methoxy-5-(phenylmethoxy)-3-isoquinolinecarboxylate |
| KR20190140011A (ko) | 2017-04-28 | 2019-12-18 | 아사나 바이오사이언시스 엘엘씨 | 아토피성 피부염을 치료하고, 활성 약학적 성분의 안정성을 개선하기 위한 제형물, 방법, 키트, 및 투여형 |
| ES2878313T3 (es) * | 2017-06-09 | 2021-11-18 | Shandong Danhong Pharmaceutical Co Ltd | Derivado de ácido carboxílico como antagonista del receptor de AT2R |
| GB201710906D0 (en) * | 2017-07-06 | 2017-08-23 | Vicore Pharma Ab | Compounds and methods for treating peripheral neuropathy |
| US11905274B2 (en) | 2018-02-23 | 2024-02-20 | Beijing Tide Pharmaceutical Co., Ltd. | Receptor inhibitors, pharmaceutical compositions comprising the same and use thereof |
| KR20210010444A (ko) * | 2018-03-23 | 2021-01-27 | 베이징 타이드 파마슈티컬 코퍼레이션 리미티드 | 수용체 억제제, 이를 포함하는 약학적 조성물 및 이의 용도 |
| WO2019238962A1 (en) * | 2018-06-14 | 2019-12-19 | University College Cork - National University Of Ireland, Cork | Peptide for disease treatment |
| WO2020012266A1 (en) | 2018-07-12 | 2020-01-16 | Novartis Ag | Biocatalytic synthesis of olodanrigan (ema401) from 3-(2-(benzyloxy)-3-methoxyphenyl)propenoic acid with phenylalanine ammonia lyase |
| KR20240063881A (ko) | 2021-07-30 | 2024-05-13 | 콘포 테라퓨틱스 엔.브이. | 통증, 특히 신경병증성 통증, 및/또는 at2r 및/또는 at2r 매개 신호전달과 연관된 다른 질환 또는 장애의 치료를 위한 화합물 |
| WO2023224853A1 (en) | 2022-05-17 | 2023-11-23 | Eli Lilly And Company | At2r antagonists and uses thereof |
Family Cites Families (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3531485A (en) * | 1967-08-14 | 1970-09-29 | American Home Prod | Aryl-substituted diazabicycloalkanes |
| US3957795A (en) * | 1974-01-28 | 1976-05-18 | Delmar Chemicals Limited | Novel cyclopentene and cyclopentane derivatives |
| US3975795A (en) | 1975-01-20 | 1976-08-24 | Union Carbide Corporation | Product stuffing apparatus and method |
| US4812462A (en) | 1986-04-01 | 1989-03-14 | Warner-Lambert Company | 4,5,6,7-tetrahydro-1H-imidazo[4,5-c]pyridine-6-carboxylic acid analogs having antihypertensive activity |
| US5091390A (en) | 1990-09-20 | 1992-02-25 | E. I. Du Pont De Nemours And Company | Treatment of CNS disorders with 4,5,6,7-tetrahydro-1H-imidazo (4,5-)-pyridines and analogs |
| CA2093125C (en) | 1990-10-02 | 2003-12-16 | Warner-Lambert Company | Angiotensin ii antagonists |
| US5385894A (en) * | 1991-03-06 | 1995-01-31 | Merck & Co., Inc. | Disubstituted 6-aminoquinazolinones |
| US5238942A (en) | 1991-05-10 | 1993-08-24 | Merck & Co., Inc. | Substituted quinazolinones bearing acidic functional groups as angiotensin ii antagonists |
| WO1992020661A1 (en) * | 1991-05-22 | 1992-11-26 | Merck & Co., Inc. | N, n-diacylpiperazines |
| US5204354A (en) * | 1992-02-14 | 1993-04-20 | Merck & Co., Inc. | Substituted quinazolinones as neurotensin antagonists useful in the treatment of CNS disorders |
| NZ251741A (en) | 1992-04-13 | 1997-06-24 | Zeneca Ltd | Use of angiotensin ii antagonists for treating disease conditions associated with impaired neuronal conduction velocity |
| GB9208116D0 (en) | 1992-04-13 | 1992-05-27 | Ici Plc | Therapeutic agents |
| US5246943A (en) | 1992-05-19 | 1993-09-21 | Warner-Lambert Company | Substituted 1,2,3,4-tetahydroisoquinolines with angiotensin II receptor antagonist properties |
| US5236934A (en) | 1992-08-26 | 1993-08-17 | E. I. Du Pont De Nemours And Company | 1,2,3,4-tetrahydroisoquinolines useful in the treatment of CNS disorders |
| US5344830A (en) | 1992-12-10 | 1994-09-06 | Merck & Co., Inc. | N,N-diacylpiperazine tachykinin antagonists |
| HUT71557A (en) * | 1992-12-11 | 1995-12-28 | Ciba Geigy Ag | Substituted benzazepinones, process for producing them and pharmaceutical compositions containing them |
| US5395844A (en) | 1993-06-10 | 1995-03-07 | The Du Pont Merck Pharmaceutical Company | Imidazole 5-position substituted angiotensin II antagonists |
| US5348955A (en) | 1993-06-22 | 1994-09-20 | Merck & Co., Inc. | N,N-diacylpiperazines |
| US5338740A (en) | 1993-07-13 | 1994-08-16 | Pfizer Inc. | Angiotensin II receptor antagonists |
| AP9400651A0 (en) | 1993-07-15 | 1995-12-30 | Pfizer | Azacyclic-heterocyclic compounds as angiotensin II receptor antagonists. |
| US5409926A (en) | 1993-07-19 | 1995-04-25 | Merck & Co., Inc. | AT-2 antagonist inhibition of vascular restenosis |
| US5610165A (en) | 1994-02-17 | 1997-03-11 | Merck & Co., Inc. | N-acylpiperidine tachykinin antagonists |
| FR2739625B1 (fr) | 1995-10-09 | 1997-12-05 | Atochem Elf Sa | Copolymeres hydrosolubles associatifs triblocs |
| GB2323783A (en) | 1997-04-02 | 1998-10-07 | Ferring Bv Group Holdings | Inhibitors of farnesyl protein transferase |
| WO1999007413A1 (en) | 1997-08-11 | 1999-02-18 | Algos Pharmaceutical Corporation | Substance p inhibitors in combination with nmda-blockers for treating pain |
| US6277839B1 (en) | 1998-10-07 | 2001-08-21 | Merck Frosst Canada & Co. | Biphenylene lactams as prostaglandin receptor ligands |
| ATE354364T1 (de) * | 1998-12-23 | 2007-03-15 | Novartis Pharma Gmbh | Verwendung von at-1 rezeptorantagonisten oder at- 2 rezeptormodulatoren zur behandlung von erkrankungen, die mit einer erhöhung an at-1 oder at-2 rezeptoren verbunden sind |
| ATE339417T1 (de) * | 1999-12-15 | 2006-10-15 | Bristol Myers Squibb Co | Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten |
| WO2001043761A2 (en) | 1999-12-16 | 2001-06-21 | University Of Southern California | Methods for treating and preventing damage to mucosal tissue |
| US6653332B2 (en) | 2000-05-03 | 2003-11-25 | Tularik Inc. | Combination therapeutic compositions and method of use |
| AU2001282886A1 (en) | 2000-07-13 | 2002-01-30 | Pharmacia Corporation | Combination of a cox-2 inhibitor and a vasomodulator for treating pain and headache pain |
| EP1333824B1 (en) | 2000-11-17 | 2005-09-07 | Warner-Lambert Company LLC | Treatment of sexual dysfunction with bombesin receptor antagonists |
| EG23054A (en) | 2001-01-22 | 2004-02-29 | Sankyo Co | Pyrrole derivatives their preparation and their therapeutic uses |
| AU2002245340A1 (en) | 2001-01-29 | 2002-08-12 | Cognetix, Inc. | B-superfamily conotoxins |
| EP1356815A4 (en) | 2001-01-29 | 2007-03-07 | Takeda Pharmaceutical | ANALGESIC AND ANTI-INFLAMMATORY DRUGS |
| NZ533259A (en) * | 2001-12-14 | 2007-10-26 | Targacept Inc | Methods and compositions for treatment of central nervous system disorders |
| WO2003064414A1 (en) | 2002-01-29 | 2003-08-07 | Vicore Pharma Ab. | Tricyclic compounds useful as angiotensin ii agonists |
| US6919343B2 (en) * | 2002-02-08 | 2005-07-19 | Merck & Co., Inc. | N-biphenyl(substituted methyl) aminocycloalkane-carboxamide derivatives |
| AU2003209851A1 (en) * | 2002-03-20 | 2003-09-29 | The University Of Queensland | Method of treatment and/or prophylaxis |
| JP2006500399A (ja) | 2002-04-30 | 2006-01-05 | メルク エンド カムパニー インコーポレーテッド | ナトリウムチャンネルブロッカーとしての、アリール−結合−アリール置換された、チアゾリジン−ジオンおよびオキサゾリジン−ジオン |
| CA2486302A1 (en) | 2002-05-17 | 2003-11-27 | Faust Pharmaceuticals | Methods for the prevention and/or the treatment of neurological disorders |
| GB0212412D0 (en) | 2002-05-29 | 2002-07-10 | Novartis Ag | Combination of organic compounds |
| WO2003101381A2 (en) | 2002-05-29 | 2003-12-11 | Merck & Co., Inc. | 1,2 diamido cycloalkyl sodium channel blockers |
| US20040258757A1 (en) | 2002-07-16 | 2004-12-23 | Elan Pharma International, Ltd. | Liquid dosage compositions of stable nanoparticulate active agents |
| JO2397B1 (en) * | 2002-12-20 | 2007-06-17 | ميرك شارب اند دوم كوربوريشن | Terazol derivatives as beta-hydroxy steroid dihydrogenase-1 inhibitors |
| DE10300973A1 (de) * | 2003-01-14 | 2004-07-22 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Carbonsäuren und deren Ester, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
| PA8597401A1 (es) * | 2003-03-14 | 2005-05-24 | Pfizer | Derivados del acido 3-(1-[3-(1,3-benzotiazol-6-il) propilcarbamoil] cicloalquil) propanoico como inhibidores de nep |
| WO2004099248A2 (en) | 2003-05-05 | 2004-11-18 | Bayer Healthcare Ag | Diagnostics and therapeutics for diseases associated with g-protein-coupled receptor agtr2 (agtr2) |
| US7157584B2 (en) | 2004-02-25 | 2007-01-02 | Takeda Pharmaceutical Company Limited | Benzimidazole derivative and use thereof |
| ES2425567T3 (es) | 2004-12-24 | 2013-10-16 | Spinifex Pharmaceuticals Pty Ltd | Método de tratamiento o profilaxis |
| AU2007249399A1 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
-
2005
- 2005-12-23 ES ES05821524T patent/ES2425567T3/es active Active
- 2005-12-23 EP EP20130162564 patent/EP2650010A1/en not_active Withdrawn
- 2005-12-23 DK DK05821524T patent/DK1830869T3/da active
- 2005-12-23 US US11/315,354 patent/US7795275B2/en not_active Expired - Fee Related
- 2005-12-23 EP EP20130162570 patent/EP2650011A1/en not_active Withdrawn
- 2005-12-23 NZ NZ555334A patent/NZ555334A/en not_active IP Right Cessation
- 2005-12-23 CN CN2005800441997A patent/CN101087619B/zh not_active Expired - Fee Related
- 2005-12-23 SI SI200531764T patent/SI1830869T1/sl unknown
- 2005-12-23 PL PL05821524T patent/PL1830869T3/pl unknown
- 2005-12-23 PT PT58215245T patent/PT1830869E/pt unknown
- 2005-12-23 WO PCT/AU2005/001975 patent/WO2006066361A1/en active Application Filing
- 2005-12-23 ME MEP-2013-88A patent/ME01597B/me unknown
- 2005-12-23 EP EP20050821524 patent/EP1830869B1/en active Active
- 2005-12-23 CN CN2010105444424A patent/CN102049048B/zh not_active Expired - Fee Related
- 2005-12-23 CN CN201210208621.XA patent/CN102861019B/zh not_active Expired - Fee Related
- 2005-12-23 JP JP2007547106A patent/JP4966202B2/ja active Active
- 2005-12-23 RS RSP20130354 patent/RS52927B/en unknown
-
2007
- 2007-06-20 ZA ZA2007/04909A patent/ZA200704909B/en unknown
- 2007-11-05 HK HK07111990A patent/HK1103364A1/xx not_active IP Right Cessation
-
2010
- 2010-08-03 US US12/849,727 patent/US8492382B2/en not_active Expired - Fee Related
-
2011
- 2011-06-24 US US13/167,980 patent/US8404686B2/en not_active Expired - Fee Related
-
2012
- 2012-10-01 ZA ZA2012/07322A patent/ZA201207322B/en unknown
- 2012-10-01 ZA ZA2012/07323A patent/ZA201207323B/en unknown
-
2013
- 2013-06-20 US US13/923,085 patent/US8722675B2/en not_active Expired - Fee Related
- 2013-08-06 HR HRP20130738TT patent/HRP20130738T1/hr unknown
- 2013-08-13 CY CY20131100691T patent/CY1114424T1/el unknown
-
2014
- 2014-03-28 US US14/229,746 patent/US9018207B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130738T1 (hr) | Postupak lijeäśenja ili profilakse | |
| IL277183B2 (en) | Bicyclic compounds as inhibitors of pd1/pd-l1 interaction/activation | |
| RU2391341C2 (ru) | Индазолы, бензотиазолы, бензоизотиазолы, их получение и применение | |
| HRP20161657T1 (hr) | Kinazolinoni kao inhibitori humane fosfatidilinozitol 3- kinaze delta | |
| BR0104228A (pt) | Derivados do ácido de alquilamino úteis como agentes farmacêuticos, método para fabricação de um composto, composição farmacêutica, métodos para tratamentos diversos e uso de um composto na fabricação de um medicamento para tratamentos diversos | |
| HRP20130900T1 (hr) | Derivat (aza)indola i njegova uporaba u medicinske svrhe | |
| HRP20090593T1 (hr) | Derivati benzimidazola i njihova uporaba kao antagonista aii receptora | |
| HRP20171415T4 (hr) | Heterociklični spojevi za liječenje neuroloških i psiholoških poremećaja | |
| MX2023005984A (es) | Nuevos agentes antivirales derivados de la espiropirrolidina. | |
| PT2420491E (pt) | Compostos de piperidina 3,5-substituída como inibidores de renina | |
| JP2008509187A5 (hr) | ||
| EA023500B1 (ru) | Соединения, композиции и способы их применения для коррекции уровня мочевой кислоты | |
| DE122006000051I2 (de) | Ester der 5-Aminolevulinsäure als Mittel zur Photosensibilisierung in der Chemotherapie | |
| HRP20140011T1 (hr) | Derivati oksazina i njihova uporaba u lijeäśenju neuroloških poremeä†aja | |
| AR055303A1 (es) | Derivados de triazol sustituidos como antagonistas de oxitocina, composicion farmaceutica y uso del compuesto para preparar un medicamento | |
| FR2903107B1 (fr) | Derives d'imidazopyridine-2-carboxamides, leur preparation et leur application en therapeutique | |
| HRP20230977T1 (hr) | Derivati 3-(((((2s,5r)-2-karbamoil-7-okso-1,6-diazabiciklo[3.2.1]oktan-6- il)oksi)sulfonil)oksi)-2,2-dimetilpropanoata i srodni spojevi kao peroralno primijenjeni predlijekovi inhibitora beta-laktamaze namijenjenih liječenju bakterijskih infekcija | |
| PT1227806E (pt) | Formulacao farmaceutica contendo tolterodina e sua utilizacao | |
| DE60319269D1 (de) | Pharmazeutische verwendungen von 2-substituierten 4-heteroarylpyrimidinen | |
| SI2315587T1 (en) | A therapeutic composition comprising macitentan | |
| HRP20240173T1 (hr) | Fluorofenil beta-hidroksietilamini i njihova upotreba u liječenju hiperglikemije | |
| HRP20130007T1 (hr) | Lijeäśenje kognitivnih poremeä†aja pomoä†u (r)-7-kloro-n-(kinuklidin-3-il)benzo[b]tiofen-2-karboksamida i njegovih farmaceutski prihvatljivih soli | |
| HRP20210158T1 (hr) | Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku | |
| HRP20171692T1 (hr) | Derivati karbamat/uree | |
| RU2011111117A (ru) | Лечение аутоиммунных заболеваний |